BRAF and melanoma: For example, in melanoma, increased production of VEGF or increased expression or activation of the platelet-derived growth factor receptor β or insulin like growth factor 1 receptor is associated with resistance to BRAF inhibitors demonstrating mechanisms cancer cells use to overcome single target modalities [64].